Conformis

History

2023: Restor3d bought Conformis

In late June 2023, Restor3d and Conformis announced a final agreement to buy Conformis. The transaction price is $2.27 per share, which is 96% more than the quotation rate as of June 22, 2023.

The board of directors of Conformis unanimously approved the deal in early June 2023. According to the press release, the board of directors decided that the transaction was in the best interests of the company's shareholders, Conformis.

Restor3d and Conformis announce final agreement to buy Conformis

According to Restor3d CEO Kurt Jacobus, this merger will create a leading company for the production of personalized 3D-printed medical devices. Together, companies share a common belief in the power of personalization. Jacobus added that leveraging the strengths of our portfolios in AI-based implant design, digital automation, and 3D printed osteointegrative biomaterials, we see a tremendous opportunity to offer clinically differentiated and cost-effective solutions in orthopedics, including the shoulder, foot, and ankle, spine, and large joints.

Restor3d and Conformis expect the deal to close by the end of the third quarter of 2023. It must be approved by Conformis shareholders and other customary closing conditions met.

According to the Global Industry Report for June 2023, the global market for knee implants and related medical products by 2024 will be about $4 billion. The main drivers of growth will be an increase in the number of minimally invasive surgeries using precision personified guides, an increase in the geriatric population, and the prevalence of arthritis.^[1]

Notes